Revalia Bio
revaliabio.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$26.8M
2 rounds on record
Latest round
$14.5M
Seed · Sep 2025 · 13 mo ago
Team
19
US Form 5500 (plan participants) · Dec 2025 · +19% in a year
Backers
1
Sierra Ventures
The money's age
Due for its next round
13 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 7, 2025
Raised a round Seed $14.5M
Oct 25, 2024
Raised a round Venture round $12.3M · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Sep 2025 | $14.5M | — | tennessean.com |
| Venture round | Oct 2024 | $12.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Revalia Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Gregory TietjenExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Sierra Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Watershed Bio is a biocomputing software company whose platform lets scientists run biological data analysis, discovery and collaboration…
Siena AI is a software company that builds an autonomous customer service platform for consumer and e-commerce brands. Its AI agents use…
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Enterprise-grade interaction infrastructure that enables real-time, multi-peer collaboration between agents and humans through a shared…
Leverage the power of Pitchly agents and generative AI to transform the way you create pitchbooks and digital assets.
Ochre Bio is a London biotechnology company founded in 2019 that develops RNA medicines for chronic liver disease. It tests candidates on…
News
Revalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data Trials
Read more
Report
Revalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data Trials
Read more
Report
Revalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data Trials
Funding backs a human-first approach to drug safety and efficacy, reducing reliance on animal testing and accelerating therapies for patients. NEW HAVEN, CT / ACCESS Newswire / December 5, 2025 / Revalia Bio(Revalia), developer of the Human Data Trial ...
Read more
Report
Revalia Bio Raises $14.5M Seed Round to Launch Human Data Trial Platform and Redefine Drug Development
Read more
Report
National Kidney Foundation invests in health tech company Revalia Bio
The National Kidney Foundation Innovation Fund has invested in health technology company Revalia Bio, according to a press release. "This investment serves as an important catalyst for advancing how new therapies are developed and delivered," Kevin Longin
Read more
Report
People
Gregory Tietjen
Executive Officer, Director
Milad Alucozai
Director
Brian Wilcove
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New Haven
United States
HQ
10-50 est. staff